1989
DOI: 10.1002/jso.2930410407
|View full text |Cite
|
Sign up to set email alerts
|

Cyclic and sequential therapy with tamoxifen and medroxyprogesterone acetate in metastatic breast cancer

Abstract: A clinical trial of sequential tamoxifen and medroxyprogesterone acetate (MPA) was carried out in 36 women with metastatic breast cancer in order to evaluate the therapeutic efficacy of this regimen and to determine if tamoxifen would increase progesterone receptor (PR) levels and thereby increase response to MPA. Fourteen patients (39%) responded to this treatment, with the duration of remission ranging from 2 to 24 + months (the mean and median were 11 months). In 22 patients, PR levels were measured both be… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

1992
1992
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 2 publications
1
0
0
Order By: Relevance
“…28 AMG treatment is also associated with a variety of IDRs that include drug fever. 29 In our study, AMG treatment led to an increase in neutrophilassociated cytokines, G-CSF and TNF-α. Moreover, TNF-α can stimulate the neutrophil respiratory burst by activating NADPH oxidase, and this could increase the formation of reactive metabolites.…”
Section: ■ Discussionsupporting
confidence: 55%
“…28 AMG treatment is also associated with a variety of IDRs that include drug fever. 29 In our study, AMG treatment led to an increase in neutrophilassociated cytokines, G-CSF and TNF-α. Moreover, TNF-α can stimulate the neutrophil respiratory burst by activating NADPH oxidase, and this could increase the formation of reactive metabolites.…”
Section: ■ Discussionsupporting
confidence: 55%